Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | MET | P08581 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 4/20 | 0.47 |
| ▸ | NPC1 | O15118 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | NAMPT | P43490 | 1/20 | 0.45 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.44 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15068379 | 1.00 | KMT2A (0.52) | KMT2AMEN1KDM4ELMNAPOLB | |
| SCHEMBL15068422 | 0.91 | SMN1; SMN2 (0.48) | KMT2AMEN1KDM4ELMNAPOLB | |
| SCHEMBL15068419 | 0.91 | SMN1; SMN2 (0.48) | KMT2AMEN1KDM4ELMNAPOLB | |
| SCHEMBL15065794 | 0.89 | SMN1; SMN2 (0.52) | KMT2AMEN1KDM4ELMNAPOLB | |
| SCHEMBL15065795 | 0.89 | SMN1; SMN2 (0.52) | KMT2AMEN1KDM4ELMNAPOLB | |
| SCHEMBL15065389 | 0.87 | NPC1 (0.58) | KMT2AMEN1SMN1; SMN2L3MBTL1RAB9A | |
| SCHEMBL15065392 | 0.87 | NPC1 (0.58) | KMT2AMEN1SMN1; SMN2L3MBTL1RAB9A | |
| SCHEMBL15065919 | 0.85 | KMT2A (0.53) | KMT2AMEN1LMNASMN1; SMN2L3MBTL1 | |
| SCHEMBL15065917 | 0.85 | KMT2A (0.53) | KMT2AMEN1LMNASMN1; SMN2L3MBTL1 | |
| SCHEMBL15066458 | 0.83 | HDAC4 (0.51) | KMT2AMEN1ALDH1A1CYP2C9CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150045367-A1 | CINNAMIC ACID HYDROXYAMIDES AS INHIBITORS OF HISTONE DEACETYLASE 8 | PHARMACYCLICS LLC | 2015-02-12 | — | — | US | claimed |
| EP-2797875-A1 | CINNAMIC ACID HYDROXYAMIDES AS INHIBITORS OF HISTONE DEACETYLASE 8 | Pharmacyclics, Inc. (US) | 2014-11-05 | — | — | EP | claimed |
| WO-2013101600-A1 | CINNAMIC ACID HYDROXYAMIDES AS INHIBITORS OF HISTONE DEACETYLASE 8 | PHARMACYCLICS, INC. (US) | 2013-07-04 | — | — | WO | claimed |
| US-20150045367-A1 | CINNAMIC ACID HYDROXYAMIDES AS INHIBITORS OF HISTONE DEACETYLASE 8 | PHARMACYCLICS LLC | 2015-02-12 | — | — | US | disclosed |
| EP-2797875-A1 | CINNAMIC ACID HYDROXYAMIDES AS INHIBITORS OF HISTONE DEACETYLASE 8 | Pharmacyclics, Inc. (US) | 2014-11-05 | — | — | EP | disclosed |
| WO-2013101600-A1 | CINNAMIC ACID HYDROXYAMIDES AS INHIBITORS OF HISTONE DEACETYLASE 8 | PHARMACYCLICS, INC. (US) | 2013-07-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150045367-A1 | CINNAMIC ACID HYDROXYAMIDES AS INHIBITORS OF HISTONE DEACETYLASE 8 | HDAC8, HDAC5, HDAC7 | KMT2A 91/4885MEN1 2526/4885KDM4E 781/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.